| Date | Form | Description | Docs | XBRL | Pages |
| 06/26/14 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 06/26/14 | DEF 14A | Definitive proxy statements |
|
59 | |
| 06/17/14 | UPLOAD | SEC-generated letter |
|
1 | |
| 06/16/14 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | |
| 06/16/14 | PRER14A | Preliminary revised proxy soliciting materials |
|
49 | |
| 06/16/14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
63 |
| 06/13/14 | UPLOAD | SEC-generated letter |
|
2 | |
| 06/03/14 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
48 | |
| 05/30/14 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 05/08/14 | EFFECT | Notice of Effectiveness |
|
1 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...